Preclinical Prostate Cancer Models:
Which One is Right For You?
Presented by: Dr. Rajendra Kumari, Crown Bioscience
Preclinical prostate cancer research is hampered by a lack of predictive models to investigate tumorigenesis and develop new treatment strategies. Preclinical models are difficult to develop, leaving current drug discovery efforts bottlenecked by the limited number of models truly reflecting the diversity of human disease.
In this webinar Dr. Rajendra Kumari, Global Head of Scientific Communication at Crown Bioscience will review currently available preclinical prostate cancer models. She’ll highlight the advantages and limitations of each model for prostate cancer drug discovery.
The webinar will deep dive into the range of models needed for comprehensive oncology and immuno-oncology agent development. Well-characterized xenograft models, including patient-derived xenografts (PDX) are required to tackle evolution of the disease. Immunocompetent models including syngeneics, tumor homografts, and humanized models help in understanding tumor-host interactions, which are key to the development of novel immunotherapies.
Watch this Webinar to:
- Learn how to overcome challenges in developing preclinical models across all stages of prostate cancer including CRPC
- Understand the key advantages and limitations of currently available prostate cancer preclinical models
- Explore panels of xenograft models, and learn when to move to more translational PDX for clinically relevant data
- Discover how to choose the correct immunocompetent murine model for your prostate cancer research from syngeneics and tumor homografts
- Learn when to use humanized models in prostate cancer immunotherapy development
About The Presenter:
After receiving her Ph.D from the University of Leicester in Molecular Pharmacology, Rajendra joined the lab of Prof. Sue Watson as a postdoctoral fellow in the Division of Pre-clinical Oncology, School of Clinical Sciences, University of Nottingham (UoN). In 2005, Rajendra took the role of Project and Business Manager of the Preclinical Oncology Services (PRECOS) contract research business unit where she built up and managed the portfolio of preclinical in vitro and in vivo projects, products, team and clients, as well as marketing and developing the commercial processes of PRECOS.
Rajendra’s expertise in cancer cell biology and model development helped to build PRECOS, develop an academic career as a lecturer in the School of Clinical Sciences, as well as co-founding the Ex Vivo Pharmacology Centre of Excellence (UoN), which recapitulates the tumor microenvironment through use of clinically-derived tissue. Rajendra was pivotal in the growth of the business unit and commercialization of research which led to the establishment of the spinout of PRECOS Ltd in 2010, acting as Chief Operations Officer, Board Director and co-founder, until merger with Crown Bioscience in July 2013. Rajendra acted as GM/CSO for CrownBio UK for 4 years, and is now the Global Head of Scientific Communications across CrownBio, providing scientific guidance and communications on company products, services, and R&D.
Rajendra is a member of the American Association of Cancer Research, British Association of Cancer Research, the NC3Rs Cancer Research Advisory Group, and has authored over 40 abstracts and publications.